Skip to main content

Amphastar Pharmaceutical Value Stock - Dividend - Research Selection

Amphastar Pharmaceuticals Inc.

ISIN: US03209R1032, WKN: A11664

Market price date: 02.06.2021
Market price: 18,85 USD




Amphastar Pharmaceuticals Inc. Fundamental data and company key figures of the share

Annual reports in USD
Key figures 17-03-2021
Cash flow
Net operating cash flow 57.266.000
Capital Expenditures -33.855.000
Free cash flow 23.411.000
Balance sheet
Total Equity 402.306.000
Liabilities & Shareholders equity 631.236.000
Income statement
Net income 1.403.000
Eps (diluted) 0,030
Diluted shares outstanding 42.090.000
Net sales/revenue 349.846.000

Fundamental ratios calculated on: 02-06-2021

Ratios
Key figures 02-06-2021
Cash flow
P/C 13,86
   
P/FC 33,89
Balance sheet
ROI0,22
ROE63,73
Income statement
P/E628,33
Div. Yield0,00%
P/B1,97
P/S2,27


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAMPH
Market Capitalization793.396.480,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetir.amphastar.com


Description of the company

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, ir.amphastar.com